Today, on 29 April, the JSC Grindeks submitted the audited consolidated financial statements of 2015 to Nasdaq Riga. Audited financial results indicate that the Group’s...
JSC Grindeks, the manufacturer of Mildronate® (meldonium), has submitted an open letter to the World Anti-Doping Agency (WADA). According to the JSC Grindeks, WADA has...
There’s really no evidence that there’s any performance enhancement from meldonium, said Don Catlin, a long-time anti-doping expert and the scientific director of the Banned...
Despite Grindeks submitted arguments, evidence and justifications, the World Anti-Doping Agency (WADA) included meldonium in the Prohibited list. In accordance with the results of the...
Today, on 26 February, the JSC Grindeks submitted the non-audited consolidated financial statements of 2015 to Nasdaq Riga. Non-audited financial results indicate that the Group’s...
JSC Grindeks will publish its: non-audited financial statement for the 12-month period of 2015 on February 26, 2016; non-audited interim financial statement for the 3-month...
Today, on 27 November, the JSC Grindeks submitted the non-audited consolidated financial statements for the nine months of 2015 to “Nasdaq Riga”. Non-audited financial results...
From 13th to 15th of October, 2015, Grindeks and its subsidiary “Kalceks” participate in the leading pharmaceutical exhibition “CPhI Worldwide 2015” in Madrid, Spain. During...
JSC Grindeks announces that due to technical issues JSC Grindeks announcements published in the Nasdaq news distribution service system (GlobeNewswire) on 09 January, 2015, 27...
